- Home
- USEA vs ALLR Comparison
USEA vs ALLR Comparison
Compare USEA & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | ALLR |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 19.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | USEA | ALLR |
|---|---|---|
| Price | $2.09 | $1.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 31.9K | ★ 120.8K |
| Earning Date | 05-21-2026 | 05-15-2026 |
| Dividend Yield | ★ 11.39% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $320,000.00 |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.77 |
| 52 Week High | $2.28 | $2.35 |
Technical Indicators
Market Signals| Indicator | USEA | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 47.79 | 63.51 |
| Support Level | $2.00 | $1.00 |
| Resistance Level | $2.23 | $1.42 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 20.00 | 76.70 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.